Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 123,770

Document Document Title
WO/2017/093519A1
The invention relates to dextrorphan-derivatives, pharmaceutical compositions and pharmaceutical dosage forms containing such dextrorphan-derivatives as well as the use of those dextrorphan-derivatives and/or compositions for treating an...  
WO/2017/093449A1
A composition comprising medium-chain triglycerides (MCTs) wherein the composition comprises (i) a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and (ii) a MCT comprising three fatty acid moieties each with 1...  
WO/2017/096298A1
Provided herein are compounds that act as histone deacetylase (HDAC) inhibitors, and can affect expression of genes in vivo and in vitro. These HDAC inhibitors are generally volatile compounds that can be administered as a gas or vapor. ...  
WO/2017/095237A1
The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to prot...  
WO/2017/095458A1
This invention generally relates to a composition and method of using recombinant microRNAs (miRNA) and their hairpin-like precursors (pre-miRNA) as therapeutic drugs for treating Alzheimer's diseases (AD). More specifically, the present...  
WO/2017/095904A1
Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding. For example, heterobifunctional compounds that inhibit both E-selectins and P-selectins are described, wherein the selectin ...  
WO/2017/093718A1
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatingenzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin S...  
WO/2017/093897A1
Compositions comprising an antioxidant directed or indirectly conjugated to an aromatic-cationic peptide are provide. Said antioxidants are selected from TEMPO, Tro, PBN, AHDP, DBHP, Caf and Hem and may be conjugated to the aromatic-cati...  
WO/2017/093060A1
A medium-chain triglyceride (MCT) or medium-chain fatty acid (MCFA) for use in improving cognition which has been impaired by UBE3A deficiency.  
WO/2017/095759A1
In its many embodiments, the present invention provides certain C5-C6-carbocyclic fused iminothiazine dioxide compounds, including compounds Formula (I): and tautomers thereof, and pharmaceutically acceptable salts of said compounds and ...  
WO/2017/093363A1
The present invention is directed to a compound for use in the prevention or treatment of a neurodegenerative disease, in particular of a synucleinopathy. The present invention further is directed to a pharmaceutical composition containi...  
WO/2017/093807A1
The present invention relates generally to methods for the treatment and/or prophylaxis of mental illness involving administration of 10-HDA. More particularly, methods are taught herein for the treatment and/or prophylaxis of obsessive ...  
WO/2017/092638A1
The present invention relates to an opioid receptor antagonist derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to a naloxone derivative as shown by general formula (I) ...  
WO/2017/093890A1
The present invention relates to a pharmaceutical composition comprising clobazam or its pharmaceutically acceptable salt(s) or solvate(s) thereof of defined particle size and one or more pharmaceutically acceptable excipients.  
WO/2017/090716A1
The present invention provides type I crystals and type II crystals of 4-(2,5-dimethylpyrimidin-4-yl)-N-(6-fluoro-2-phenyl-[1,2,4]t riazolo[1,5-a]pyridin-7-yl)-1-methyl-1H-pyrazole-5-carboxami de that have an exceptional phosphodiesteras...  
WO/2017/088755A1
Disclosed hereinis an aminopyrimidine heterocyclic compound with adenosine receptor antagonistic activity, comprising a compound of the general formula (I), or a pharmaceutically acceptable salt thereof. The aminopyrimidine heterocyclic ...  
WO/2017/088731A1
The present invention relates to octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof, and pharmaceutical compositions containing these compounds. The compounds or the pharmaceutical compositions are used for antagonizing orexin re...  
WO/2017/088723A1
The present invention relates to a class of substituted triazolopiperazine compounds represented by general formula (I), tautomers, enantiomers, diastereomers, racemates, metabolites, metabolic precursors, and pharmaceutically acceptable...  
WO/2017/091661A1
The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to...  
WO/2017/088177A1
The present invention discloses a use of mussel adhesive proteins or a preparation thereof in preventing and suppressing a neuronal inflammation, and particularly discloses a use of mussel adhesive proteins or a preparation thereof in ne...  
WO/2017/089892A1
The present application relates to a compound of Formula (I), and to uses thereof, such the treatment of a neurological or psychoartic disorder.  
WO/2017/088759A1
The invention relates to octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof. Compounds and pharmaceutical compositions comprising the compounds provided herein are used for antagonizing orexin receptors. The invention also re...  
WO/2017/089458A1
The present invention relates to compound of formula (I) (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as...  
WO/2017/091827A1
The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxycodone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal u...  
WO/2017/089606A1
The present invention relates to a therapy for the treatment of demyelination, including multiple sclerosis, based upon suppressing the action of Ephrin-B1, Ephrin-B2 and Ephrin-B3. The demyelination may also be associated with other dis...  
WO/2017/088725A1
Disclosed are compounds as shown in General Formula (I), a preparation method therefor, and uses thereof. The compounds are weak in GPR17 antagonistic activity and strong in CysLT1 antagonism, can be used for preventing and treating cent...  
WO/2017/091719A1
The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.  
WO/2017/091592A1
The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, n, ring A, X2, L, m, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and comp...  
WO/2017/091072A1
This invention relates to preparations comprising a butyrate salt for enteral administration for use in the treatment of conditions and diseases that are not diseases or conditions of the intestine and/or are associated with systemic inf...  
WO/2017/086835A1
The present invention relates to the chemical and pharmaceutical industries and medicine, and pertains to means for treating demyelinating diseases. A pharmaceutical composition in solid dosage form, exhibiting a therapeutic effect with ...  
WO/2017/085655A1
The present invention relates to compositions with a synergistic action between a mucoadherent gelling complex against the passage of antigens, and immunomodulatory anti-IL17 bacteria for use in the treatment of IL-17-related autoimmune ...  
WO/2017/085733A3
The disclosure herein provides certain analgesic 2,6-xylidine derivatives or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions for...  
WO/2017/087373A1
The invention relates to a modified release abuse deterrent tablet and a method for preparing the modified release abuse deterrent tablet.  
WO/2017/087594A1
Disclose are amine prodrugs and methods of synthesis thereof. In particular, the amine prodrug comprises a drug molecule and at least one or more prodrug appendage moieties and the method for synthesis the amine prodmg comprises a step o...  
WO/2017/085502A1
The present invention provides a transdermal delivery device comprising a pharmaceutical composition, wherein said composition comprises a N-oxide derivative of an opioid antagonist, or a salt thereof, and an opioid agonist or salt thereof.  
WO/2017/087445A1
The present invention provides methods of treating MS using pyrimidine and pyridine compounds which are inhibitors of Bruton's tyrosine kinase (BTK).  
WO/2017/085035A1
The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs,...  
WO/2017/085198A1
The present invention relates to derivativesof formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pha...  
WO/2017/085350A1
The present invention relates to a combination comprising galanin and [Leu31,Pro34]NPY, and to the use of said combination for a disease of the nervous system, particularly depression. The invention also relates to a screening method for...  
WO/2017/085734A1
The present invention relates to crystalline forms of Tapentadol salts and process for preparation thereof. The structural formula of Tapentadol salts is represented as follows: [Formula should be inserted here].  
WO/2017/083983A1
The present disclosure generally relates to compounds comprising homotaurine that may be used in improving the general mental condition and/or general brain function of a non- human animal, and for the prophylaxis of chronic, aging-relat...  
WO/2017/087965A1
Processes and compositions for 2-heteroaryl substituted benzofuran derivatives are described. The 2-heteroaryl substituted benzofuran derivatives may be suitable for preparing radiolabeled 2-heteroaryl substituted benzofuran derivatives ...  
WO/2017/085362A1
The present invention is directed to a composition for intranasal administration comprising a CDNF polypeptide for use in the intranasal treatment of a central nervous system disease, such as Alzheimer's disease, Parkinson's disease, mul...  
WO/2017/085483A1
The present invention relates to compounds of formulae I, or pharmaceutically acceptable salts or esters thereof, wherein: R1 is selected from H and CO-NR8R9, wherein R8 and R9 are each independently selected from H, alkyl, cycloalkyl an...  
WO/2017/085317A1
The invention discloses using secreted splicing variant of mammal Klotho (s- KL) as an agent for the prevention and/or treatment of cognitive and/or behaviour impairments. It also refers to gene constructs and expression vectors useful i...  
WO/2017/087905A1
Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such...  
WO/2017/087500A1
Disclosed herein are neural extracellular vesicles (EVs) and methods of using these EVs in the treatment of spinal cord injury, stroke, and traumatic brain injury and neurodegenerative diseases.  
WO/2017/084752A1
The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to oxadiazaspiro compounds having this pharmacological activity, to processes of preparation of such compou...  
WO/2017/085437A1
The present invention relates to combinations for use in the treatment of various forms of dementia of mild, moderate and severe degree, including mild cognitive impairment, alcoholic dementia, vascular dementia, Alzheimer's disease, Lew...  
WO/2017/087282A1
The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, includin...  

Matches 201 - 250 out of 123,770